Targeting the WNT pathway to treat advanced cancers
Tumor selective inhibition of the WNT pathway
This study is looking at a new way to slow down cancer growth by targeting a specific pathway that’s often too active in cancers like colorectal, breast, and lung cancer, and it aims to create treatments that work well for patients while being gentle on healthy cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10918326 on NIH RePORTER |
What this research studies
This research investigates how to selectively inhibit the WNT signaling pathway, which is often overactive in various cancers, including colorectal, breast, and lung cancers. By using advanced techniques like CRISPR and focusing on tumor-specific mechanisms, the study aims to develop therapies that can effectively reduce cancer cell growth while minimizing side effects on healthy tissues. The approach seeks to differentiate between cancerous and normal cells to provide targeted treatment options for patients with advanced malignancies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old with advanced cancers that exhibit hyperactivation of the WNT pathway.
Not a fit: Patients with early-stage cancers or those whose tumors do not involve the WNT signaling pathway may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with advanced cancers by specifically targeting tumor cells without harming normal tissues.
How similar studies have performed: Previous research has shown promising results in targeting the WNT pathway in pre-clinical models, indicating potential for success in this novel approach.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Dow, Lukas Edward — Weill Medical Coll of Cornell Univ
- Study coordinator: Dow, Lukas Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.